People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Basking Biosciences, Inc. | — | Biotechnology | Series B | $29.4M | $261.0M | 2023 |
| Syrna Therapeutics, Inc. | — | Biotechnology | Series A | $10.9M | $88.8M | 2023 |
Aiden Aceves at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Aiden Aceves on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steve Gillis | 1 | 13 |
| David Adair | 1 | 7 |
| Ryan Helon | 1 | 5 |
| Richard Shea | 1 | 5 |
| David Weitz | 1 | 4 |
| Thomas Needham | 1 | 4 |
| Dan Myers | 1 | 3 |
| Hannah Chang | 1 | 2 |
| Julia Owens | 1 | 2 |
| Joel Dudley | 1 | 2 |
| Shahid Nimjee | 1 | 1 |
| Bruce Sullenger | 1 | 1 |
| Thomas Hermann | 1 | 1 |
| Ari Nowacek | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.